Friday, July 10, 2026
🇺🇸 FDA

pharma · Advanced Solid Tumors · Agitation Associated with Alzheimer’s Disease

Bristol-Myers Squibb Australia

Bristol-Myers Squibb Australia Pty Ltd

Bristol-Myers Squibb Australia drug portfolio — 120 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
PO Box 1080, Mount Waverley, Victoria 3149, Australia HQ
6 Employees
TGA registrant Type
Company details
Status
Public
HQ
PO Box 1080, Mount Waverley, Victoria 3149, Australia
Employees
6
Programs
93
Drugs
120
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Drug Pipeline

Bristol-Myers Squibb Australia pipeline

Portfolio lens on 120 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Bristol-Myers Squibb Australia drug portfolio — 120 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

120 compounds

  1. abatacept

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: T-lymphocyte activation antigen CD80.

    Target
    T-lymphocyte activation antigen CD80
    Mechanism
    T-lymphocyte activation antigen CD80 inhibitor

  2. adagrasib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: GTPase KRas.

    Target
    GTPase KRas
    Mechanism
    GTPase KRas inhibitor

  3. adalimumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  5. alzheimer

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  6. antagonist

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  7. anti-

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  8. anti-melanoma mab fragments

    Various (V09)

    Various (V09) compound in Bristol-Myers Squibb Australia's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  9. apixaban

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: Coagulation factor X.

    Target
    Coagulation factor X
    Mechanism
    Coagulation factor X inhibitor

  10. apremilast

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Phosphodiesterase 4.

    Target
    Phosphodiesterase 4
    Mechanism
    Phosphodiesterase 4 inhibitor

  11. atazanavir

    Antiinfectives for systemic use (J05)

    Antiinfectives for systemic use (J05) compound in Bristol-Myers Squibb Australia's portfolio.

  12. atazanavir + cobicistat

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  13. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  14. atropine sulfate

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.

    Target
    Muscarinic acetylcholine receptor M1
    Mechanism
    Muscarinic acetylcholine receptor M3 antagonist

  15. azacitidine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.

    Target
    DNA (cytosine-5)-methyltransferase 1
    Mechanism
    DNA (cytosine-5)-methyltransferase 3A inhibitor

  16. betamethasone dipropionate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  17. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  18. bnt327

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  19. cabozantinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Mechanism: Hepatocyte growth factor receptor inhibitor.

    Mechanism
    Hepatocyte growth factor receptor inhibitor

  20. cabozantinib s-malate

    US regulatory status: approved. Molecular target: Hepatocyte growth factor receptor.

    Target
    Hepatocyte growth factor receptor
    Mechanism
    Hepatocyte growth factor receptor inhibitor

  21. calcium

    US regulatory status: approved.

  22. capecitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  23. capsule

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  24. capsules

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  25. car-t

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  26. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  27. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  28. cells

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  29. cend-

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  30. cetuximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  31. chloride

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  32. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  33. combination

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  34. crizotinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.

    Target
    ALK tyrosine kinase receptor
    Mechanism
    Hepatocyte growth factor receptor inhibitor

  35. cyclophosphamide

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  36. daratumumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  37. dasatinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.

    Target
    Bcr/Abl fusion protein
    Mechanism
    SRC inhibitor

  38. deucravacitinib

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Non-receptor tyrosine-protein kinase TYK2.

    Target
    Non-receptor tyrosine-protein kinase TYK2
    Mechanism
    Tyrosine-protein kinase TYK2 negative allosteric modulator

  39. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  40. dextrose

    US regulatory status: approved.

  41. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bristol-Myers Squibb Australia's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  43. durvalumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  44. elotuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: SLAM family member 7.

    Target
    SLAM family member 7
    Mechanism
    SLAM family member 7 inhibitor

  45. eribulin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bristol-Myers Squibb Australia's portfolio. Mechanism: Tubulin inhibitor.

    Mechanism
    Tubulin inhibitor

  46. etoposide

    US regulatory status: approved. Molecular target: DNA topoisomerase II.

    Target
    DNA topoisomerase II
    Mechanism
    DNA topoisomerase II inhibitor

  47. fedratinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bristol-Myers Squibb Australia's portfolio. Molecular target: Tyrosine-protein kinase JAK2.

    Target
    Tyrosine-protein kinase JAK2
    Mechanism
    Tyrosine-protein kinase JAK2 inhibitor

  48. filgrastim

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.

    Target
    Granulocyte colony-stimulating factor receptor
    Mechanism
    Granulocyte colony stimulating factor receptor agonist

  49. fingolimod

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Mechanism: Sphingosine 1-phosphate receptor binding agent.

    Mechanism
    Sphingosine 1-phosphate receptor binding agent

  50. fludarabine

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  51. fludarabine phosphate

    US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).

    Target
    DNA polymerase (alpha/delta/epsilon)
    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  52. fluorouracil

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  53. gemcitabine

    US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.

    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  54. hema-

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  55. hexocyclium methylsulfate

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.

    Target
    Muscarinic acetylcholine receptor M1
    Mechanism
    Muscarinic acetylcholine receptor M1 antagonist

  56. imatinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bristol-Myers Squibb Australia's portfolio. Mechanism: Tyrosine-protein kinase ABL inhibitor.

    Mechanism
    Tyrosine-protein kinase ABL inhibitor

  57. infusion

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  58. inhibitor

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  59. inhibitors

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  60. injection

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  61. intravenous

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  62. ipilimumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.

    Target
    Cytotoxic T-lymphocyte protein 4
    Mechanism
    Cytotoxic T-lymphocyte protein 4 inhibitor

  63. irinotecan

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.

    Mechanism
    DNA topoisomerase I inhibitor

  64. irinotecan hydrochloride

    US regulatory status: approved. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I inhibitor

  65. irinotecan hydrochloride trihydrate

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bristol-Myers Squibb Australia's portfolio. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I inhibitor

  66. lamivudine

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  67. lenalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  68. lenvatinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bristol-Myers Squibb Australia's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.

    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  69. lenvatinib mesylate

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.

    Target
    Vascular endothelial growth factor receptor
    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  70. lisocabtagene maraleucel

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bristol-Myers Squibb Australia's portfolio. Molecular target: B-lymphocyte antigen CD19.

    Target
    B-lymphocyte antigen CD19
    Mechanism
    B-lymphocyte antigen CD19 binding agent

  71. malignant

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  72. matching

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  73. mavacamten

    Cardiovascular system (C01)

    US regulatory status: approved. Molecular target: Cardiac myosin.

    Target
    Cardiac myosin
    Mechanism
    Cardiac myosin inhibitor

  74. methotrexate

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Dihydrofolate reductase inhibitor

  75. monotherapy

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  76. nivolumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  77. nivolumab + relatlimab

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  79. osimertinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bristol-Myers Squibb Australia's portfolio. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  80. osimertinib mesylate

    US regulatory status: approved. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  81. oxaliplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  82. ozanimod

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Sphingosine 1-phosphate receptor 5.

    Target
    Sphingosine 1-phosphate receptor 5
    Mechanism
    Sphingosine 1-phosphate receptor Edg-1 modulator

  83. paclitaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  84. palonosetron

    Alimentary tract and metabolism (A04)

    Alimentary tract and metabolism (A04) compound in Bristol-Myers Squibb Australia's portfolio. Mechanism: Serotonin 3a (5-HT3a) receptor antagonist.

    Mechanism
    Serotonin 3a (5-HT3a) receptor antagonist

  85. pegfilgrastim

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.

    Target
    Granulocyte colony-stimulating factor receptor
    Mechanism
    Granulocyte colony stimulating factor receptor agonist

  86. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  87. pemetrexed disodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  88. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  89. peritoneal

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  90. placebo

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  91. powder

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  92. progression

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  93. regorafenib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Discoidin domain-containing receptor 2.

    Target
    Discoidin domain-containing receptor 2
    Mechanism
    Fibroblast growth factor receptor 2 inhibitor

  94. relatlimab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bristol-Myers Squibb Australia's portfolio. Molecular target: Lymphocyte activation gene 3 protein.

    Target
    Lymphocyte activation gene 3 protein
    Mechanism
    Lymphocyte activation gene 3 protein inhibitor

  95. repotrectinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: CD74-ROS1.

    Target
    CD74-ROS1
    Mechanism
    CD74-ROS1 inhibitor

  96. rituximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  97. rucaparib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bristol-Myers Squibb Australia's portfolio. Molecular target: PARP 1, 2 and 3.

    Target
    PARP 1, 2 and 3
    Mechanism
    PARP 1, 2 and 3 inhibitor

  98. ruxolitinib

    Dermatologicals (D11)

    US regulatory status: approved. Mechanism: Tyrosine-protein kinase JAK2 inhibitor.

    Mechanism
    Tyrosine-protein kinase JAK2 inhibitor

  100. sodium chloride solution

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  101. solution

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  102. sorafenib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bristol-Myers Squibb Australia's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.

    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  103. stro-

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  104. subcutaneous

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  105. sunitinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bristol-Myers Squibb Australia's portfolio. Molecular target: Macrophage colony-stimulating factor 1 receptor.

    Target
    Macrophage colony-stimulating factor 1 receptor
    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  106. t-cell

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  107. tablet

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  108. tablets

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  109. targeted

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  110. temozolomide

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  111. thalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  112. therapy

    Development asset linked to Bristol-Myers Squibb Australia in public FDA and regional records.

  113. tocilizumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.

    Target
    Interleukin-6 receptor subunit alpha
    Mechanism
    Interleukin-6 receptor alpha subunit inhibitor

  114. topotecan hydrochloride

    US regulatory status: approved. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I, mitochondrial inhibitor

  115. trametinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase; MEK1/2.

    Target
    Dual specificity mitogen-activated protein kinase kinase; MEK1/2
    Mechanism
    Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor

  116. trametinib dimethyl sulfoxide

    US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.

    Target
    Dual specificity mitogen-activated protein kinase kinase 1
    Mechanism
    Dual specificity mitogen-activated protein kinase kinase 2 inhibitor

  117. trifluridine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  118. trospium chloride

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M2.

    Target
    Muscarinic acetylcholine receptor M2
    Mechanism
    Muscarinic acetylcholine receptor M2 antagonist

  119. ustekinumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-12.

    Target
    Interleukin-12
    Mechanism
    Interleukin-23 inhibitor

  120. venetoclax

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.

    Target
    Apoptosis regulator Bcl-2
    Mechanism
    Apoptosis regulator Bcl-2 inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.